However, it appears that first-line treatment with endocrine therapy and CDK4/6 inhibitors in patients with ER+ and HER2- breast cancer is likely effective for the treatment of choroidal metastases secondary to ER+/HER2- breast cancer and may allow a delay in the use of local invasive interventions. The gene discussed is CDK4; the disease is breast carcinoma.